Compare Incyte Corporation (INCY) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Matson Inc — how do they compare? Incyte Corporation trades at $120.58 (market cap $24.54B), while Matson Inc trades at $214.5 (market cap $6.11B). The key difference: Incyte Corporation is far larger — about 4× Matson Inc's market cap, and Matson Inc pays a 0.74% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MATX | |
|---|---|---|
Market Cap | $24.54B | $6.11B |
Sector | Health | Technology |
52-Week High | $129.93 | $223.55 |
52-Week Low | $81.61 | $88.05 |
Enterprise Value | $20.04B | $6.71B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Matson (MATX) trades at $214.52, up 2.8% today, with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, a 13.41% net margin, and robust cash flow generation. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 estimate, driving positive analyst sentiment.
Outlook remains positive with 27% upside to consensus target of $265. Key risks include shipping industry cyclicality and global trade volatility. The combination of strong earnings momentum, attractive valuation at 13.79 P/E, and institutional support supports a constructive investment case for the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
